RAB5A and Lewy body dementia: Clinical trials aimed at pharmacologically attenuating rab5 overactivation have shown encouraging improvement in measures of cholinergic function in Lewy body dementia, a disorder in which BFCN loss of function contributes prominently to the clinical presentation (Jiang et al., 2022).